Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI1341 in Healthy Male and Female Volunteers

NCT03272165 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03272165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03272165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI1341 in Healthy Male and Female Volunteers
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
October 17, 2017
Completion date
March 31, 2021
Enrollment
50 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease